Technology
Health
Biotechnology

Kodiak Sciences

$6.99
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.03 (-0.43%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell KOD and other stocks, options, ETFs, and crypto commission-free!

About

Kodiak Sciences, Inc. develops novel therapies for the treatment of retinal diseases. Its preclinical stage product candidates include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases; KSI-201, a recombinant mammalian cell expressed dual inhibitor antibody biopolymer bioconjugate for the treatment of wet AMD; and KSI-401, a recombinant mammalian cell expressed antibody biopolymer conjugate for the treatment of dry AMD. Read More The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Employees
28
Headquarters
Palo Alto, California
Founded
2009
Market Cap
258.55M
Price-Earnings Ratio
Dividend Yield
Average Volume
96.74K
High Today
$7.23
Low Today
$6.99
Open Price
$7.05
Volume
77.65K
52 Week High
$11.10
52 Week Low
$5.65

Collections

Technology
Health
Biotechnology
2018 IPO
US
North America

News

MarketWatchMar 8

Kodiak Sciences Inc.

Kodiak Sciences Inc. Kodiak Sciences, Inc. develops novel therapies for the treatment of retinal diseases. Its preclinical stage product candidates include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases; KSI-201, a recombinant mammalian cell expressed dual inhibitor antibody biopolymer bioconjugate for the treatment of wet AMD; and KSI-401, a recombinant mammalian cell expressed antibody biopolymer...

163
PR NewswireMar 7

Kodiak Sciences to Present at the Barclays Global Healthcare Conference

PALO ALTO, Calif., March 7, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that management will present at the Barclays Global Healthcare Conference in Miami Beach, FL on Tuesday, March 12 at 1:35 p.m. Eastern Time. A live audio webcast of the presentation will be available on the "Investor Relations" section of Kodiak's website at http://ir.kodiak.com/...

120

Earnings

-$1.33
-$0.99
-$0.64
-$0.30
Q3 2018
Q4 2018
Estimated
-$0.30 per share
Actual
Expected Mar 21, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.